Oak Ridge, TN, May 14, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), Daxor Corporation, the global leader in blood volume measurement technology, today announces significant new findings from Duke University Medical Center published in the prestigious American Heart Journal. The research demonstrates how Blood Volume Analysis (BVA) enables precise measurement of red blood cell mass (RBCM) and effectively differentiates between true and dilutional anemia in heart failure (HF) patients. Published ...

Core Insights - Daxor Corporation will showcase its advanced blood volume analysis technology at the 45th International Society for Heart and Lung Transplantation Annual Meeting, which will take place from April 27-30, 2025, in Boston, MA, attracting around 3,500 specialists in heart and lung disease treatment [1][2] Company Overview - Daxor Corporation is recognized as the global leader in blood volume measurement technology, having developed the BVA-100® (Blood Volume Analyzer), the only FDA-cleared diagnostic blood test for quantifying blood volume status and composition [3] - Over 65,000 tests have been conducted at leading hospitals in the U.S., significantly improving hospital performance metrics and reducing mortality and readmissions in heart failure and critical care [3] - The company is engaged in ongoing trials for heart failure treatment with support from the NIH and is also developing analyzers for combat casualty care in collaboration with the U.S. Department of Defense [3] Technology and Impact - Daxor's diagnostic technology provides 98% accurate data, facilitating personalized treatment for end-stage heart and lung patients, which enhances patient outcomes while lowering care duration and costs [2]

Core Insights - WellStar Health System's Advanced Heart Failure program has successfully reduced acute kidney injury rates following left ventricular assist device implantation through a blood volume analysis (BVA) approach [2] - Daxor Corporation will showcase its BVA technology at the MedAxiom CV Transforum Spring'25 Conference, emphasizing its role in improving patient outcomes [1][3] - BVA-guided care has demonstrated significant improvements in patient outcomes, including an 82% reduction in 30-day mortality, an 86% reduction in 1-year mortality, a 56% reduction in 30-day readmissions, and a 55% reduction in length of stay when implemented at admission [4] Company Overview - Daxor Corporation is a leader in blood volume measurement technology, known for its BVA-100® (Blood Volume Analyzer), which is FDA-cleared for accurate quantification of blood volume status [5] - Over 65,000 BVA tests have been conducted in leading U.S. hospitals, contributing to improved performance metrics in various medical conditions, particularly in heart failure and critical care [5] - Daxor is involved in ongoing trials for heart failure treatment with support from the NIH and is developing analyzers for combat casualty care in collaboration with the U.S. Department of Defense [5] Industry Context - MedAxiom serves as a premier source for organizational performance solutions in the cardiovascular community, aiming to enhance outcomes, reduce costs, and improve patient and clinician experiences [6] - The MedAxiom CV Transforum conference brings together cardiovascular thought leaders and industry innovators to advance cardiovascular care [1][6]